Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11880520 | 0.95 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2HRH3KMT2AMEN1 | |
| SCHEMBL2257602 | 0.85 | SIGMAR1 (0.59) | ALDH1A1HRH3SIGMAR1GAAACHE | |
| SCHEMBL5817187 | 0.84 | ACHE (0.56) | SMN1; SMN2HRH3SIGMAR1ACHEBACE1 | |
| SCHEMBL17155418 | 0.83 | HRH3 (0.49) | HRH3SIGMAR1GAAFAAHACHE | |
| SCHEMBL17153150 | 0.78 | MAPK1 (0.65) | ALDH1A1SMN1; SMN2KMT2AMEN1SIGMAR1 | |
| SCHEMBL16225922 | 0.77 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2KMT2AMEN1SIGMAR1 | |
| SCHEMBL14013779 | 0.75 | HRH3 (0.52) | ALDH1A1HRH3KMT2AMEN1SIGMAR1 | |
| SCHEMBL13739501 | 0.75 | HDAC2 (0.55) | SMN1; SMN2KMT2AMEN1SIGMAR1NPC1 | |
| SCHEMBL5547852 | 0.75 | LMNA (0.61) | ALDH1A1HRH3SIGMAR1MAPK1GAA | |
| SCHEMBL10407610 | 0.75 | EP300 (0.58) | KMT2AMEN1SIGMAR1ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2916833-A1 | METHODS OF TREATING LIVER DISEASES | Zafgen, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014071368-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-7019016-B2 | Therapy of sensorineural hearing loss in a mammal by administering NR2B subunit selective N-methyl-D-aspartate (NMDA) NR2B subtype receptor antagonist | PFIZER INC (US) | 2006-03-28 | — | — | US | disclosed |
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2003-07-31 | — | — | US | disclosed |
| US-6534522-B2 | E.g.,N-((4-amino-3-nitrophenoxy)ethyl)-1,2,3,4-tetrahydro -isoquinoline; stroke; antiischemic agents; CNS trauma, hyperglycemic agents; surgery; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis | WARNER-LAMBERT COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2001-12-13 | — | — | US | disclosed |
| US-6218404-B1 | THERAPY AND PROPHYLAXIS OF NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CNS TRAUMA, HYPOGLYCEMIA AND SURGERY, NEURO-DEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE | WARNER-LAMBERT CO. | 2001-04-17 | — | — | US | disclosed |
| WO-1997023458-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | ALDH1A1 2672/4885SMN1; SMN2 274/4885HRH3 1326/4885 |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | ALDH1A1 2672/4885SMN1; SMN2 274/4885HRH3 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.